←
Elsa Renee Flores553 posts
Elsa Renee Flores avatar

Elsa Renee Flores

@LabElsaFlores

Moffitt Cancer Center ACD & Division Chief, Basic Science. Cancer Biologist. Discovery Science.

◷ Joined February 2020▧ 48 Photos and videos
Moffitt Cancer Center avatar
⟳ Elsa Renee Flores retweeted
Moffitt Cancer Center@MoffittNews·Apr 20

Earlier at #AACR26, Elsa Flores, PhD (@LabElsaFlores), and Andrii Monastyrskyi, PhD, took a moment to discuss how emerging drug discovery approaches, including protein degradation and AI-driven design, are advancing new cancer therapies. #MoffittAACR26 @AACR

2:54
Laura Attardi avatar
⟳ Elsa Renee Flores retweeted
Laura Attardi@AttardiLaura·Jan 15

Thrilled to share our deconstruction of a p53 therapeutic response in #LUAD- a step toward drugging #undruggable #p53! Thanks to our amazing team! @wmx162005 @alyssamkaiser @kbieging @LabElsaFlores @MikeOzawa @MLadanyi @arati_rajeevan @rajnitin @simone_alma

Now online: p53 Drives Lung Cancer Regression through a TSC2/TFEB-Dependent Senescence Program doi.org/10.1158/2159-8290.CD…

Post attachment
Moffitt Cancer Center avatar
⟳ Elsa Renee Flores retweeted
Moffitt Cancer Center@MoffittNews·8 Nov 2025

At #SITC25, Kenneth Tsai, MD (@KYTsaiLab), presents Phase II results showing a 57.7% pCR with neoadjuvant lenvatinib plus pembrolizumab in stage II–IV Merkel cell carcinoma. Responders show interferon and ANGPTL1 signaling; nonresponders show neural and E2F/MYC pathways with higher baseline Tregs. #MoffittSITC25

3:15
Moffitt Cancer Center avatar
⟳ Elsa Renee Flores retweeted
Moffitt Cancer Center@MoffittNews·7 Nov 2025

Live from #SITC25: Kenneth Tsai, MD (@KYTsaiLab) presents data showing that Pembrolizumab plus Levatinib demonstrated encouraging efficacy as neoadjuvant therapy for resectable clinical stage II-IV Merkel cell carcinoma.

Post attachmentPost attachmentPost attachment